Das Neuroblastom: Diagnostik und Therapie mit meta-Iodbenzylguanidin

Zusammenfassung

Das Neuroblastom ist der häufigste extrakranielle solide Tumor des Kindesalters mit einem Anteil von ca. 7–10% an den pädiatrischen Malignomen und ist für etwa 15% der Krebstodesfälle im Kindesalter verantwortlich. In Deutschland erkranken etwa 130 Kinder pro Jahr. Meta-Iodbenzylguanidin (mIBG) hat sich seit der Einführung durch Dr. Donald Wieland um 1980 zu einem unverzichtbaren Bestandteil in der Diagnostik entwickelt und bietet therapeutische Möglichkeiten. Die vorliegende Arbeit basiert auf der DGN-Verfahrensanweisung zur mIBG-Szintigrafie und berücksichtigt aktuelle Entwicklungen der Diagnostik, die Methoden der PET/CT und auch aktuelle Entwicklungen in der Therapie. Für den Versorgungsstandard in Deutschland ist die Beachtung der Verfahrensanweisung zur mIBG-Szintigrafie wichtig, um eine hohe diagnostische Bildqualität zu gewährleisten. SPECT gehört zum unverzichtbaren Standard. Die Bildqualität darf nicht durch eine zu niedrig angesetzte injizierte Aktivität gefährdet werden. Hochdosis-mIBG-Therapien werden in enger Kooperation mit den Kinderonkologen durchgeführt und sollten in Zentren mit adäquater Erfahrung erfolgen.

Abstract

Neuroblastoma is the most common extracranial malignant solid tumor during childhood, accounts for about 7–10% of all pediatric malignancies and is responsible for about 15% of cancer deaths in children. In Germany, about 130 patients are diagnosed of neuroblastoma each year. Since its introduction by Dr. Donald Wieland in 1980, meta-Iodobenzylguanidine (mIBG) has become an integral part for diagnosis and therapy of neuroblastoma patients. This publication is based on the national procedure guideline for mIBG scintigraphy and includes the most recent developments in diagnosis, PET/CT methods and in mIBG therapy. For the maintenance of high medical standards an adequate image quality by adherence to the procedure guideline is mandatory. SPECT is an integral part of image acquisition. Image quality must not be jeopardized by reducing injected activity below values which are known to provide diagnostic images. High-dose mIBG therapies are usually performed in close cooperation with pediatric oncologists and should be done in centers with adequate experience.

Schlüsselwörter

Neuroblastom - I-123-meta-Iodbenzylguanidin (I-123-mIBG) - I-131-meta-Iodbenzylguanidin (I-131-mIBG)

Key words

neuroblastoma - I-123-meta-Iodobenzylguanidine (I-123-mIBG) - I-131-meta-Iodobenzylguanidine (I-131-mIBG)

• Literatur

• 1 Atas E, Kesik V, Kismet E et al. ¹³¹I-Metaiodobenzylguanidine conditioningregimen in children with neuroblastoma undergoing stemcell transplantation. Pediatr Transplant 2013; 17: 407-408
• 2 Bleeker G. The use of both diagnostic and therapeutic MIBG in neuroblastoma patients. Academisch Proefschrift. Buijten & Schipperheijn; Amsterdam: 2014. ISBN: 978-90-9028217-6
• 3 Bleeker G, Schoot RA, Caron HN et al. Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis. Eur J Nucl Med Mol Imaging 2013; 40: 1711-1717
• 4 Bombardieri E, Giammarile F, Aktolun C et al. European Association for Nuclear Medicine. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010; 37: 2436-2446
• 5 Bonnin F, Lumbroso J, Tenenbaum F et al. Refining interpretation of MIBG scans in children. J Nucl Med 1994; 35: 803-810
• 6 Brisse HJ, McCarville MB, Granata C et al. International Neuroblastoma Risk Group Project. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011; 261: 243-257
• 7 Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J ClinOncol 1993; 11: 1466-1477
• 8 Bundesamt für Strahlenschutz . Bekanntmachung der diagnostischen Referenzwerte für radiologische und nuklearmedizinische Untersuchungen. Bundesanzeiger 2003; 143: 17503-17504 (Diagnostische Referenzwerte in der Nuklearmedizin. Empfehlungen der Strahlenschutzkommission – Verabschiedet in der 167. Sitzung der Strahlenschutzkommission am 6./7. Juli 2000. 2000)
• 9 Cohn SL, Pearson AD, London WB et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27: 289-297
• 10 Decarolis B, Schneider C, Hero B et al. ¹²³I-mIBG scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J ClinOncol 2013; 31: 944-951
• 11 Du Bois S, Chesler L, Groshen S et al. Phase I Study of Vincristine, Irinotecan, and ¹³¹ I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to NeuroblastomaTherapy Trial. ClinCancer Res 2012; 18: 2679-2686
• 12 Du Bois St, Matthay KK. Radio labeled Metaiodobenzylguanidine for the Treatment of Neuroblastoma. Nucl Med Biol 2008; 35 (Suppl. 01) S35-S48
• 13 Du Bois SG, Matthay KK. 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma. Q J Nucl Med Mol Imaging 2013; 57: 53-65
• 14 Franzius C, Hermann K, Weckesser M et al. Whole-body PET/CT with C-11-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with I-123-mIBG SPECT/CT. J Nucl Med 2006; 47: 1635-1642
• 15 Franzius C, Riemann B, Vormoor J et al. Metastatic neuroblastoma demostrated by whole-body PET-CT using C-11-HED. Nuklearmedizin 2005; 44: N4-N5
• 16 Gains JE, Bomanji JB, Fersht NL et al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med 2011; 52: 1041-1047
• 17 Gaze MN, Gains JE, Walker C et al. Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma. Q J Nucl Med Mol Imaging 2013; 57: 66-78
• 18 Gelfand M. I-123-MIBG uptake in the neck and shoulders of a neuroblastoma patient: damage to sympathetic innervation blocks uptake in brown adipose tissue. Pediatr Radiol 2004; 34: 577-579
• 19 Gelfand M. Meta-iodobenzylguanidine in children. Semin Nucl Med 1993; 23: 231-242
• 20 Gelfand MJ, Elgazzar AH, Kriss VM et al. Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 1994; 35: 1753-1757
• 21 Geoerger B, Hero B, Harms D et al. Metabolic activity and clinical features of primary ganglioneuromas. Cancer 2001; 91: 1905-1913
• 22 Giammarile F, Chiti A, Lassmann M et al. EANM. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 2008; 35: 1039-1047
• 23 Giammarile F, Lumbroso J, Ricard M et al. Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high-dose on tumour site detection. Eur J Nucl Med 1995; 22: 1180-1183
• 24 Gordon I, Peters AM, Gutman A et al. Skeletal assessment in neuroblastoma – the pitfalls of iodine-123-MIBG scans. J Nucl Med 1990; 31: 129-134
• 25 Hero B, Berthold F. Neuroblastom. Leitlinie der Gesellschaft für Pädiatrische Onkologie und Hämatologie. AWMF online ( http://www.awmf.org/uploads/tx_szleitlinien/025-008l_S1_Neuroblastom_2011-08_01.pdf)
• 26 Hickeson MP, Charron M, Maris JM et al. Biodistribution of post-therapeutic versus diagnostic I-131-MIBG scans in children with neuroblastoma. Pediatr Blood Cancer 2004; 42: 268-274
• 27 Hoefnagel C, De Kraker J, Valdes Olmos R et al. [131I]MIBG as a first line treatment in advanced neuroblastoma. Q J Nucl Med 1995; 39 (Suppl. 01) 61-64
• 28 Jacobs A, Delree M, Desprechins B et al. Consolidating the role of *I-MIBG-scintigraphy in childhood neuroblastoma: five years of clinical experience. Pediatr Radiol 1990; 20: 157-159
• 29 Jacobs F, Thierens H, Piepsz A et al. Optimized tracer-dependent dosage cards to obtain weight independent effective doses. Eur J Nucl Med Mol Imaging 2005; 32: 581-588
• 30 Jacobson AF, Deng H, Lombard J et al. 123I-meta-iodobenzyl-guanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J ClinEndocrinolMetab 2010; 95: 2596-2606
• 31 Kaarsch P, Spix C. Deutsches Kinderkrebsregister, Jahresbericht 2005. Berlin: Buchdruckerei Johannes Krüger OHG; 2006
• 32 Khafagi F, Shapiro B, Fischer M et al. Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine. Eur J Nucl Med 1991; 18: 191-198
• 33 Kinnier-Wilson L, Draper G. Neuroblastoma, its natural history and prognosis: a study of 487 cases. Br Med J 1974; 3: 301-307
• 34 Knickmeier M, Schäfers M, Schober O. Two years’ experience using no-carrier-added meta-[I-123]iodobenzylguanidine in clincal studies. Eur J Nucl Med 2001; 28: 941
• 35 Kroiss A, Putzer D, Uprimny C et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging 2011; 38: 865-873
• 36 Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med 2004; 45: 1172-1188
• 37 Kushner B, Cheung N. Exploiting the MIBG-avidity of neuroblastoma for staging and treatment. Pediatr Blood Cancer 2006; 47: 863-864
• 38 Kushner B, Yeh S, Kramer K et al. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003; 21: 1082-1086
• 39 Kushner BH, Yeung HW, Larson SM et al. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18-fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001; 19: 3397-3405
• 40 Lassmann M, Biassoni L, Monieurs M et al. The New EANM Dosage Card. Eur J Nucl Med Mol Imaging 2007; 34: 796-798
• 41 Lassmann M, Biassoni L, Monsieurs M et al. EANM Dosimetry and Paediatrics Committees . The new EANM paediatric dosage card: additional notes with respect to F-18. Eur J Nucl Med Mol Imaging 2008; 35: 1666-1668 Erratum in: Eur J Nucl Med Mol Imaging 2008; 35: 2141
• 42 Lassmann M, Treves ST. Pediatric Radiopharmaceutical Administration: Harmonization of the 2007 EANM Paediatric Dosage Card (Version 1.5.2008) and the 2010 North American Consensus guideline. Eur J Nucl Med Mol Imaging 2014; 41: 1036-1041
• 43 Leung A, Shapiro B, Hattner R et al. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997; 38: 1352-1357
• 44 London WB, Boni L, Simon T et al. The role of age in neuroblastoma risk stratification: the German, Italian, and children’s oncology group perspectives. Cancer Lett 2005; 228: 257-266
• 45 Lumbroso J, Giammarile F, Hartmann O et al. Upper clavicular and cardiac meta-[123I]iodobenzylguanidine uptake in children. Q J Nucl Med 1995; 39: 17-20
• 46 Lumbroso J, Guermazi F, Hartmann O et al. Meta-iodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans. Prog Clin Biol Res 1988; 271: 689-705
• 47 Mairs R. Neuroblastoma therapy using radiolabelled [131I]meta-iodobenzylguanidine ([131I]MIBG) in combination with other agents. Eur J Cancer 1999; 35: 1171-1173
• 48 Mairs RJ, Cunningham SH, Russell J et al. No-carrier-added Iodine-131-MIBG: Evaluation of a therapeutic preparation. J Nucl Med 1995; 36: 1088-1095
• 49 Markelewicz Jr RJ, Lorenzen WA, Shusterman S et al. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy. Clin Nucl Med 2013; 38: 604-607
• 50 Matthay KK, Shulkin B, Ladenstein R et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010; 102: 1319-1326
• 51 Melzer HI, Coppenrath E, Schmid I et al. ¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging 2011; 38: 1648-1658
• 52 Messina JA, Cheng SC, Franc BL et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in pa­tients with relapsed neuroblastoma. Pediatr Blood Cancer 2006; 47: 865-874
• 53 Mueller WP, Coppenrath E, Pfluger T. Nuclear medicine and multimodality imaging of pediatric neuroblastoma. Pediatr Radiol 2013; 43: 418-427
• 54 Nakajo M, Shapiro B, Copp J et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodo-benzyl-guanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983; 24: 672-682
• 55 Naranjo A, Parisi MT, Shulkin BL et al. Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2011; 56: 1041-1045
• 56 Okuyama C, Ushijima Y, Kubota T et al. I-123-Metaiodobenzylguanidine uptake in the nape of the neck of children: likely visualization of brown adipose tissue. J Nucl Med 2003; 44: 1421-1425
• 57 Perel Y, Conway J, Kletzel M et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999; 21: 13-18
• 58 Pfluger T, Schmied C, Porn U et al. Integrated imaging using MRI and I-123-metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnodid of pediatric neuroblastoma. Am J Roentgenol 2003; 181: 1115-1124
• 59 Piccardo A, Lopci E, Conte M et al. PET/CT imaging in neuroblastoma. Q J Nucl Med Mol Imaging 2013; 57: 29-39
• 60 Piccardo A, Lopci E, Conte M et al. Comparison of (18)F-dopa PET/CT and (123)I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging 2012; 39: 57-71
• 61 Piccardo A, Puntoni M, Lopci E et al. Prognostic value of ¹⁸F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. Eur J Nucl Med Mol Imaging 2014; 41: 1046-1056
• 62 Piepsz A, Hahn K, Roca I et al. A radiopharmaceutical schedule for image in pediatric. Recommendations of the pediatric task group of the European Association of Nuclear Medicine. Eur J Nucl Med 1990; 17: 127-129
• 63 Pintelon H, Jonckheer M, Piepsz A. Paediatric nuclear medicine procedures: routine sedation or management of anxiety. Nucl Med Commun 1994; 15: 664-666
• 64 Rufini V, Giordano A, Di Giuda D et al. [123I]MIBG scintigraphy in neuroblastoma: a comparison between planar and SPECT imaging. Q J Nucl Med 1995; 4: 25-28
• 65 Sato YL, Kurosawa H, Fukushima K et al. I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma. Ital J Pediatr 2012; 38: 53
• 66 Schmidt M, Baum RP, Simon T et al. Therapeutic nuclear medicine in pediatric malignancy. Q J Nucl Med Mol Imaging 2010; 54: 411-428
• 67 Schmidt M, Hero B, Pfluger T et al. DGN-Handlungsempfehlung (S1-Leitlinie) mIBG-Szintigraphie bei Kindern Stand: 4/2013 – AWMF-Registernummer: 031-040 ( http://www.awmf.org/uploads/tx_szleitlinien/031-040l_S1_mIBG-Szintigraphie_bei_Kindern_04-2013.pdf
• 68 Schmidt M, Simon T, Hero B et al. Is there a benefit of I-131-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin 2006; 45: 145-151
• 69 Schmidt M, Simon T, Hero B et al. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma > 1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer 2008; 44: 1552-1558
• 70 Schoot RA, Bleeker G, Caron HN et al. The role of 131I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma. Eur J Nucl Med Mol Imaging 2013; 40: 1516-1522
• 71 Sharp SE, Gelfand MJ, Shulkin BL. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med 2011; 41: 345-353
• 72 Sharp SE, Shulkin BL, Gelfand MJ et al. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009; 50: 1237-1243
• 73 Shulkin BL, Hutchinson RJ, Castle VP et al. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996; 199: 743-750
• 74 Shulkin B, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998; 39: 679-688
• 75 Shulkin BL, Wieland DM, Baro ME et al. PET Hydroxyephedrine Imaging of Neuroblastoma. J Nucl Med 1996; 37: 16-21
• 76 Shulkin BL, Wieland DM, Schwaiger M et al. PET Scanning with Hydroxyephedrine: An Approach to the Localization of Pheochromocytoma. J Nucl Med 1992; 33: 1125-1131
• 77 Simon T, Hero B, Bongartz R et al. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children>1 year with residual local disease. Strahlenther Onkol 2006; 182: 389-394
• 78 Simon T, Spitz R, Faldum A et al. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 2004; 26: 791-796
• 79 Sisson J, Shulkin B. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999; 43: 217-223
• 80 Solanki K, Bomanji J, Moyes J et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992; 13: 513-521
• 81 Stabin M, Gelfand M. Dosimetry of pediatric nuclear medicine procedures. Q J Nucl Med 1998; 42: 93-112
• 82 Sudbrock F, Schmidt M, Simon T et al. Dosimetry for ¹³¹I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2010; 37: 1279-1290
• 83 Wieland D, Wu J, Brown L et al. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 1980; 21: 349-353
• 84 Wilson JS, Gains JE, Moroz V et al. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer 2014; 50: 801-815
• 85 Yanik GA, Parisi MT, Shulkin BL et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s oncology group. J Nucl Med 2013; 54: 541-548
• 86 Young JJ, Ries L, Silverberg E et al. Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer 1986; 58 (Suppl. 02) 598-602